Genedrive Share Discussion Threads

[hazl] 03/4/2024 12:12

Look at the difference!


'Current genetic testing for CYP2C19 can only be carried out using expensive machines in specialist laboratories a process which can take several weeks.

However, the Genedrive® System uses a miniaturised technology for gene reading which can be performed locally in the ward or bedside, can be used with minimal training, and rapidly provides the clinician results in around an hour.'


Several weeks....as opposed to an hour'!

Time is critical in strokes.r

[hazl] 03/4/2024 12:09

Yes a good time for me to buy.


You don't have to hooded claw.
We don't want people who don't like companies thriving!

[bigpecs] 03/4/2024 11:42

Only another 1.40 yes one pound forty to break even

[hooded claw] 03/4/2024 11:41

hazl3 Apr '24 - 11:23 - 3195 of 3200
0 0 0
Lunch time I find is quite a good time to buy.

[hazl] 03/4/2024 11:30

When a share that has been flattened unfairly and comes out with a good announcement the market reacts.


That is what has happened.
I don't ever tell people to buy I just enjoy pointing out the shorters for what they are.

[hazl] 03/4/2024 11:28

Hope The Imperialist is still here enjoying this



he has been so positive!

[hooded claw] 03/4/2024 11:27

Rage ? Hardly ... just warning people not to buy when you can't even keep up with RNS's and are saying it is a good time to buy

[hazl] 03/4/2024 11:26

We are catching up from an extreme and unfounded low, in my opinion, from over sell.


These products are not only good they are liked by the medical people.

Now NICE giving comments!

About time.

IMO

[hazl] 03/4/2024 11:23

Hilarious he is spitting with rage!

[hazl] 03/4/2024 11:23

Lunch time I find is quite a good time to buy.
Inevitably, you get people looking in that are at work and not having time to read news, they sometimes can't resist a good profit.

This gives those that have understood the importance of the announcement opportunity in my opinion.





DYOR

[hooded claw] 03/4/2024 11:21

FUNDRAISE ON THE WAY .... DO NOT LISTEN TO HAZL AS HE CAN'T EVEN KEEP UP WITH RNS'S ... IF YOU WANT TO BUY JUST WAIT A FEW WEEKS ...

From 28th March RNS

" Finally, we will seek to raise further equity funding in the coming weeks in order to provide a longer-term financing solution for the Company's exciting growth plans."

YOU HAVE BEEN WARNED

[hazl] 03/4/2024 11:18

James Cheek, CEO of genedrive plc, said: "We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test. The NHS has done significant work on both strokes and mini strokes, with campaigns for FAST (Face, Arms, Speech, Time) and promoting changing lifestyles to prevent a stroke. This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect. Clopidogrel is the NICE recommended front line treatment for these types of strokes. However, if you are one of the estimated 20%-30% who are unable to metabolise Clopidogrel effectively you have the opportunity to be identified quickly and given an alternative medication. We are delighted to be part of this change which is in line with our strategy to deliver point-of-care pharmacogenetic testing to positively impact patient outcomes. With MT-RNR1 getting a NICE EVA conditional recommendation last year, further funding applied for to achieve a full recommendation this year, a strategy in place to achieve Food and Drug Administration ("FDA") approval and sales being realised from new customers in 2024 we feel there is growing momentum within the Group's POC pharmacogenetic testing strategy."



Professor Bill Newman, Clinical Head of Division and Senior Lecturer in Clinical Genetics at Manchester University NHS Foundation Trust, said: "The DEVOTE Programme funded by Innovate UK has brought together academic, industry and clinical partners from across Manchester to deliver novel genomic diagnostics to make medicine prescription safer and more effective for patients. We have been delighted to work with genedrive to develop their point of care test which will ensure that rapid results are available to reduce the risk of patients having further strokes."

[hazl] 03/4/2024 11:17

NICE recommended in the May 2023 draft guidance that people who have just had an IS or TIA should have a CYP2C19 genetic test prior to antiplatelet treatment. Following a public consultation of this draft guidance, which ends on 26 April 2024, final recommendations are expected to be published by NICE on 10 July 2024. The public consultation documents and summary review of NICE's information can be found at:





The specialist NICE diagnostics assessment committee systematically reviewed the clinical and economic impact of genetic testing, including both laboratory-based and POC tests, concluding that it would be beneficial for people with loss-of-function CYP2C19 alleles to receive alternative antiplatelet treatment to clopidogrel and CYP2C19 genotype testing is also cost effective compared with not testing regardless of which alternative antiplatelet therapy people have.



In addition to being dominant in cost effectiveness models, NICE recommends the Genedrive® as the point-of-care platform of choice for CYP2C19 genotyping strategies in the NHS. The decision was based on several differentiating features of the Genedrive® technology; (1) its greater coverage of genetic variants compared to the other point-of-care system assessed, permitting increased equitable access to healthcare across ethnic populations, (2) no requirement for cold-chain storage logistics, (3) its ability to integrate with patient electronic healthcare systems.

[hazl] 03/4/2024 11:16

CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack


July this year publication date!


A pivotal date....in my opinion.

The shorters will be worried .
The more they post today, shows the more worried they are in my opinion!

[andymunchkin] 03/4/2024 11:15

fiVer abOOt tOgO

[andymunchkin] 03/4/2024 11:14

maaHoosive dUmping priceCrashing alMost 10% spread toSell dOnt lOOk gOOd

[hazl] 03/4/2024 11:12

genedrive plc

("genedrive" or the "Company")



NICE recommends the Genedrive® CYP2C19-ID Kit

Genedrive® CYP2C19-ID test for genotype-guided clopidogrel treatment in the NHS

chosen as the preferred platform for UK point-of-care genotype testing



genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that the UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance that the Genedrive® CYP2C19-ID test should be used as the point-of-care ("POC") test of choice before clopidogrel administration in the management of Ischemic Stroke ("IS") and Transient Ischaemic Attack ("TIA") patients.



Clopidogrel is an antiplatelet drug used after IS or TIA to reduce the risk of blood clots that can cause further strokes. Clopidogrel is metabolised into its active form by an enzyme encoded by the CYP2C19 gene which in some people has variations that reduce the enzyme's function which means that clopidogrel does not work as well in these people.



The Genedrive® CYP2C19-ID point of care genetic test uses a single, non-invasive cheek swab sample, and rapidly identifies six important genetic variants of the CYP2C19 gene, which are instrumental in the loss of metabolism function. The Genedrive® System automatically interprets the information for the clinician, allowing prompt administration of an optimised treatment plan.



According to the World Stroke Organization, there are over 77 million people globally who currently have experienced ischaemic stroke and it is estimated by the Stroke Association that there are 100,000 strokes in the UK each year. Suboptimal response to antiplatelet treatment following stroke is common, affecting about 20%-30% of patients in the general UK population, which increases to about 50%-60% in certain ethnic groups.



NICE recommended in the May 2023 draft guidance that people who have just had an IS or TIA should have a CYP2C19 genetic test prior to antiplatelet treatment. Following a public consultation of this draft guidance, which ends on 26 April 2024, final recommendations are expected to be published by NICE on 10 July 2024. The public consultation documents and summary review of NICE's information can be found at:

[hazl] 03/4/2024 11:11

Aw bless.

You still working for TW?


Having a bad day I see with GDR being 60% up.


Nevermind go and plague your other shorts you pathetic bunch.



xx

[andymunchkin] 03/4/2024 11:06

Blackhorse233 Aug '23 - 13:12 - 21 of 3181
0 0 1
Bought APH today lol
-----
hazl2 Aug '23 - 20:55 - 7 of 3181
0 1 0
Thank you aquila a fresh start and a good year working upto recognition and use of the products hopefully....to help people's lives...
-----
hazl4 Aug '23 - 10:23 - 29 of 3185
0 0 0
Don't forget we have the multi partnered award for the stroke test,too.
------
tis pump&dump sTill alIve??? hazl NuTTer been pUmping tiS fer sOlOng nUts mUst be sqUeeZeD

[hazl] 03/4/2024 11:05

Amazing what a bit of NICE can do!


Perhaps a bit of LOVELY next week



and a bit of SCRUMPTIOUS the week after?

[hazl] 03/4/2024 11:03

People are even advertising their shares here!


Absolutely hilarious!

[hazl] 03/4/2024 11:02

Hooded Claw we have had that.

Look at 15th March RNS.



Do keep up!